HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0

Historical Holders from Q1 2022 to Q3 2025

Type / Class
Debt / NOTE 0.250% 3/0
All holders as of 30 Sep 2025
Q3 2025
Total 13F principal, excl. options
726,382,500
Holdings value
$834,806,788
% of all portfolios
0.003%
Number of holders
59
Number of buys
28
Number of sells
-34
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0

Period Principal Value Change Price Investors
2025 Q3 726,382,500 $834,806,788 +$105,581,455 $1.15 59
2025 Q2 728,633,184 $726,115,830 +$9,607,370 $0.9957 64
2025 Q1 707,502,041 $750,572,002 -$21,159,427 $1.06 57
2024 Q4 713,351,051 $682,649,093 +$30,765,855 $0.9539 57
2024 Q3 685,848,882 $688,553,098 -$133,842,993 $1 54
2024 Q2 833,277,781 $795,939,589 +$12,847,273 $0.9533 58
2024 Q1 819,088,507 $726,898,751 -$345,457 $0.8867 61
2023 Q4 815,214,254 $706,534,402 +$11,603,534 $0.8644 64
2023 Q3 799,411,199 $679,095,809 +$6,210,490 $0.8445 65
2023 Q2 794,335,832 $662,252,900 +$19,666,070 $0.8328 67
2023 Q1 836,537,369 $710,137,045 +$46,468,623 $0.8478 62
2022 Q4 676,406,024 $656,553,304 -$264,456,865 $0.9714 53
2022 Q3 730,524,195 $620,620,688 +$5,561,573 $0.85 48
2022 Q2 712,881,662 $631,436,377 +$142,081,055 $0.8839 50
2022 Q1 543,043,884 $476,655,665 +$476,655,665 $0.8773 46